Study title: A double-blind, randomised, parallel group, placebo controlled multicentre study to evaluate the safety and efficacy of a range of doses of cetirizine (2.5 mg, 5 mg and 10 mg once daily) in 6 to 12-year old children suffering from perennial allergic rhinitis.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Immune System Diseases | |||||
Brands: | |||||
MAH holders: | |||||
Assessment: | |||||
Active substance: CETIRIZINE | |||||
ATC code: | |||||
Document link: A174 - Cetirizine - RRCE92H2601.pdf | |||||
Document date: 2011-11-28 | |||||
Study number: RRCE92H2601 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |